Peter Kolchinsky decreased its stake in Dicerna Pharmaceuticals Inc (DRNA) by 20.78% based on its latest 2018Q1 regulatory filing with the SEC. Ra Capital Management Llc sold 1.03M shares as the company’s stock rose 0.36% while stock markets declined. The hedge fund run by Peter Kolchinsky held 3.93M shares of the health care company at the end of 2018Q1, valued at $37.60 million, down from 4.97M at the end of the previous reported quarter. Ra Capital Management Llc who had been investing in Dicerna Pharmaceuticals Inc for a number of months, seems to be less bullish one the $660.27M market cap company. The stock decreased 0.64% or $0.08 during the last trading session, reaching $12.5. About 650,049 shares traded or 13.57% up from the average. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has risen 317.27% since June 13, 2017 and is uptrending. It has outperformed by 304.70% the S&P500. Some Historical DRNA News: 20/04/2018 – ADVISORY-Alert on Dicerna, Alnylam litigation settlement wrongly coded to American Lorain; 23/03/2018 – Report: Exploring Fundamental Drivers Behind Goldfield, Dicerna Pharmaceuticals, Deciphera Pharmaceuticals, WesBanco, Carolina; 19/04/2018 – DJ Dicerna Pharmaceuticals Inc, Inst Holders, 1Q 2018 (DRNA); 20/04/2018 – ALNYLAM – AS PER SETTLEMENT, DICERNA WILL BE RESTRICTED IN ITS DEVELOPMENT RELATING TO OLIGONUCLEOTIDE-BASED THERAPEUTICS FOR A DEFINED SET OF CO’S TARGETS; 20/04/2018 – Alnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation and Other Pending; 17/05/2018 – Dicerna Treatment Granted Orphan Drug Status by FDA; 20/04/2018 – DICERNA PHARMACEUTICALS INC – DICERNA WILL DISMISS ALL COUNTERCLAIMS ASSOCIATED WITH ALNYLAM’S TRADE SECRET MISAPPROPRIATION LITIGATION; 03/04/2018 – Dicerna at HC Wainwright Global Biotechnology Conference Apr 10; 20/04/2018 – DICERNA REPORTS SETTLEMENT OF ALL LITIGATION WITH ALNYLAM; 20/04/2018 – Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam
Hillcrest Asset Management Llc increased its stake in Argo Group Intl Hldg F (AGII) by 10.71% based on its latest 2018Q1 regulatory filing with the SEC. Hillcrest Asset Management Llc bought 18,616 shares as the company’s stock 0.00% . The institutional investor held 192,392 shares of the finance company at the end of 2018Q1, valued at $11.04M, up from 173,776 at the end of the previous reported quarter. Hillcrest Asset Management Llc who had been investing in Argo Group Intl Hldg F for a number of months, seems to be bullish on the $1.98B market cap company. The stock increased 5.37% or $3 during the last trading session, reaching $58.85. About 195,111 shares traded or 34.18% up from the average. Argo Group International Holdings, Ltd. (NASDAQ:AGII) has 0.00% since June 13, 2017 and is . It has underperformed by 12.57% the S&P500. Some Historical AGII News: 14/03/2018 – Argo Group Forms Golden Cross: Technicals; 13/03/2018 – ARGO GROUP REPORTS PURCHASE OF ARISCOM; 13/03/2018 – Argo Group Announces Acquisition Of Ariscom; 19/03/2018 – Argo Group Non-Deal Roadshow Scheduled By JMP for Mar. 22; 21/03/2018 – DGAP-NEWS: ARGO GOLD ENTERS INTO AGREEMENT TO SELL ROCKSTAR GOLD PROPERTY; 15/03/2018 – Report: Exploring Fundamental Drivers Behind Mountain Province Diamonds, Limoneira, Arsanis, ExlService, Argo Group Internation; 13/03/2018 – ARGO GROUP INTERNATIONAL HOLDINGS – ACQUIRED ITALIAN SPECIALTY INSURER ARISCOM. EFFECTIVE IMMEDIATELY; 02/04/2018 – Argo Translation’s CMS Connect™ Plugin Makes Content Management Translation, Updates Easy; 23/04/2018 – Argo Group to Transfer Listing to NYSE from NASDAQ; 05/04/2018 – ARGO GOLD COMPLETES SALE OF ROCKSTAR GOLD PROPERTY
Hillcrest Asset Management Llc, which manages about $111.61 million and $497.10M US Long portfolio, decreased its stake in Global Brass &Copper (NYSE:BRSS) by 58,527 shares to 162,335 shares, valued at $5.43M in 2018Q1, according to the filing. It also reduced its holding in Apogee Enterprises (NASDAQ:APOG) by 7,692 shares in the quarter, leaving it with 200,036 shares, and cut its stake in Amern Eqty Invt Life (NYSE:AEL).
Investors sentiment increased to 2.39 in Q1 2018. Its up 1.44, from 0.95 in 2017Q4. It improved, as 22 investors sold AGII shares while 24 reduced holdings. 20 funds opened positions while 90 raised stakes. 29.00 million shares or 17.48% more from 24.69 million shares in 2017Q4 were reported. Tci Wealth has 445 shares. Tiaa Cref Invest Mngmt Limited Liability Co stated it has 0.03% in Argo Group International Holdings, Ltd. (NASDAQ:AGII). Prelude Capital Llc holds 0% or 890 shares in its portfolio. Timessquare Capital Ltd Com holds 0.15% of its portfolio in Argo Group International Holdings, Ltd. (NASDAQ:AGII) for 372,440 shares. Thrivent Financial For Lutherans invested in 354,419 shares or 0.07% of the stock. Swiss Comml Bank owns 60,916 shares or 0% of their US portfolio. Proshare Ltd Llc has invested 0% in Argo Group International Holdings, Ltd. (NASDAQ:AGII). Lord Abbett Co Llc has invested 0.14% in Argo Group International Holdings, Ltd. (NASDAQ:AGII). Spectrum Mgmt Grp Inc accumulated 0.01% or 577 shares. Teacher Retirement Systems Of Texas stated it has 0% in Argo Group International Holdings, Ltd. (NASDAQ:AGII). Moreover, Citigroup Incorporated has 0% invested in Argo Group International Holdings, Ltd. (NASDAQ:AGII). Moreover, Dean Cap Management has 2.28% invested in Argo Group International Holdings, Ltd. (NASDAQ:AGII). Ameriprise Inc reported 511,176 shares. Tributary Capital Management Ltd Liability Co owns 263,843 shares for 1.27% of their portfolio. American Intl Grp Incorporated has invested 0% of its portfolio in Argo Group International Holdings, Ltd. (NASDAQ:AGII).
Among 5 analysts covering Argo Group International Holdings (NASDAQ:AGII), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Argo Group International Holdings had 7 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was initiated by JMP Securities with “Mkt Perform” on Monday, June 27. The firm has “Buy” rating given on Thursday, December 28 by Keefe Bruyette & Woods. The rating was maintained by Keefe Bruyette & Woods on Monday, September 18 with “Hold”. The stock has “Overweight” rating by Piper Jaffray on Thursday, December 10. Wood upgraded the shares of AGII in report on Thursday, December 28 to “Outperform” rating. The rating was maintained by Keefe Bruyette & Woods with “Market Perform” on Friday, May 13.
Investors sentiment decreased to 2.44 in Q1 2018. Its down 0.56, from 3 in 2017Q4. It dropped, as 3 investors sold DRNA shares while 13 reduced holdings. 24 funds opened positions while 15 raised stakes. 30.68 million shares or 5.45% more from 29.10 million shares in 2017Q4 were reported. California Pub Employees Retirement Sys has 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Manchester Cap Mngmt Lc has invested 0.03% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). 11,794 were reported by Quantitative Systematic Strategies Ltd Limited Liability Company. Goldman Sachs stated it has 788,604 shares or 0% of all its holdings. Ecor1 Cap Ltd Liability Company reported 4.76M shares. Deutsche State Bank Ag invested in 2,200 shares. Emerald Mutual Fund Advisers Tru holds 0.06% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 151,571 shares. Vanguard Group Inc holds 0% or 1.23 million shares. Blackrock holds 0% or 277,493 shares. Renaissance Limited Liability Com holds 0% or 289,400 shares. Eam Investors Limited holds 47,286 shares or 0.08% of its portfolio. Virtu Fin Limited Co owns 14,416 shares for 0.01% of their portfolio. Bogle Invest Management Lp De, Massachusetts-based fund reported 18,798 shares. Northern Trust holds 59,384 shares or 0% of its portfolio. Parallax Volatility Advisers Lp reported 798 shares.
More news for Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) were recently published by: Nasdaq.com, which released: “Research Report Identifies Carolina Financial, Dicerna Pharmaceuticals, On Assignment, Digimarc, CIRCOR …” on May 18, 2018. Investingnews.com‘s article titled: “Dicerna Doses First Primary Hyperoxaluria Patient with DCR-PHXC in Group B Portion of PHYOX Phase 1 Clinical Trial” and published on May 30, 2018 is yet another important article.
Analysts await Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) to report earnings on August, 9. They expect $-0.42 earnings per share, up 63.48% or $0.73 from last year’s $-1.15 per share. After $-0.30 actual earnings per share reported by Dicerna Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 40.00% negative EPS growth.
Among 9 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 4 have Buy rating, 0 Sell and 5 Hold. Therefore 44% are positive. Dicerna Pharmaceuticals had 25 analyst reports since August 7, 2015 according to SRatingsIntel. As per Monday, August 10, the company rating was maintained by Stifel Nicolaus. The company was maintained on Friday, August 11 by H.C. Wainwright. On Friday, March 9 the stock rating was maintained by Stifel Nicolaus with “Buy”. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Buy” rating by H.C. Wainwright on Monday, December 12. Stifel Nicolaus maintained the shares of DRNA in report on Thursday, June 30 with “Buy” rating. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Buy” rating by Cowen & Co on Tuesday, July 18. The firm earned “Hold” rating on Friday, August 11 by Chardan Capital Markets. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has “Neutral” rating given on Friday, March 23 by H.C. Wainwright. The company was maintained on Wednesday, August 16 by Cowen & Co. The firm earned “Buy” rating on Monday, February 5 by SunTrust.